Published in J Biol Inorg Chem on November 18, 2010
Inhibition of DNA Synthesis by a Platinum-Acridine Hybrid Agent Leads to Potent Cell Kill in Non-Small Cell Lung Cancer. ACS Med Chem Lett (2011) 1.06
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev (2016) 1.02
Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells. Metallomics (2012) 0.98
Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair. Mol Pharm (2011) 0.95
Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents. ACS Chem Biol (2012) 0.92
Unusual Reactivity of a Potent Platinum-Acridine Hybrid Antitumor Agent. ACS Med Chem Lett (2011) 0.91
Using a build-and-click approach for producing structural and functional diversity in DNA-targeted hybrid anticancer agents. J Med Chem (2012) 0.90
Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents. J Med Chem (2012) 0.82
Interactions of a platinum-modified perylene derivative with the human telomeric G-quadruplex. J Phys Chem B (2011) 0.81
Cellular Recognition and Repair of Monofunctional-Intercalative Platinum-DNA Adducts. Chem Res Toxicol (2015) 0.78
PT-ACRAMTU, a platinum-acridine anticancer agent, lengthens and aggregates, but does not stiffen or soften DNA. Cell Biochem Biophys (2013) 0.77
Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. J Inorg Biochem (2016) 0.76
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem (2007) 2.44
A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer. J Med Chem (2008) 1.36
Design, synthesis, and biological activity of a novel non-cisplatin-type platinum-acridine pharmacophore. J Med Chem (2001) 1.32
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer (2000) 1.31
Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure. J Am Chem Soc (2004) 1.26
Structure-activity relationships in platinum-acridinylthiourea conjugates: effect of the thiourea nonleaving group on drug stability, nucleobase affinity, and in vitro cytotoxicity. J Biol Inorg Chem (2004) 1.18
Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting. Dalton Trans (2009) 1.17
Synthesis, biological activity, and DNA-damage profile of platinum-threading intercalator conjugates designed to target adenine. J Med Chem (2006) 1.14
Effect of the diamine nonleaving group in platinum-acridinylthiourea conjugates on DNA damage and cytotoxicity. J Med Chem (2007) 1.12
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer (2007) 1.11
Unprecedented monofunctional metalation of adenine nucleobase in guanine- and thymine-containing dinucleotide sequences by a cytotoxic platinum-acridine hybrid agent. J Am Chem Soc (2003) 1.09
Adenine-N3 in the DNA minor groove - an emerging target for platinum containing anticancer pharmacophores. Anticancer Agents Med Chem (2007) 1.07
Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. Curr Top Med Chem (2004) 1.05
Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates. Biochem Pharmacol (2002) 1.03
Metal-intercalator-mediated self-association and one-dimensional aggregation in the structure of the excised major DNA adduct of a platinum-acridine agent. J Am Chem Soc (2004) 1.00
Unique base-step recognition by a platinum-acridinylthiourea conjugate leads to a DNA damage profile complementary to that of the anticancer drug cisplatin. Biochemistry (2004) 0.97
Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent. Nucleic Acids Res (2000) 0.95
Guanine binding of a cytotoxic platinum-acridin-9-ylthiourea conjugate monitored by 1-D 1H and 2-D [1H,15N] NMR spectroscopy: hydrolysis is not the rate-determining step. J Inorg Biochem (2006) 0.90
Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest. J Med Chem (2003) 0.88
Rates of platination of -AG- and -GA- containing double-stranded oligonucleotides: effect of chloride concentration. J Inorg Biochem (2000) 0.84
Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status. Biochem Pharmacol (2007) 0.83
Fast interstrand cross-linking of cisplatin-DNA monoadducts compared with intrastrand chelation: a kinetic study using hairpin-stabilized duplex oligonucleotides. Chemistry (2002) 0.83
Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo. Br J Cancer (1999) 0.83
Restriction-enzyme cleavage of DNA modified by platinum(II) complexes. Eur J Biochem (1993) 0.81
DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)]. Biochem Pharmacol (2007) 0.78
A non-cross-linking platinum-acridine agent with potent activity in non-small-cell lung cancer. J Med Chem (2008) 1.36
Structure-activity relationships in platinum-acridinylthiourea conjugates: effect of the thiourea nonleaving group on drug stability, nucleobase affinity, and in vitro cytotoxicity. J Biol Inorg Chem (2004) 1.18
Synthesis, biological activity, and DNA-damage profile of platinum-threading intercalator conjugates designed to target adenine. J Med Chem (2006) 1.14
Effect of the diamine nonleaving group in platinum-acridinylthiourea conjugates on DNA damage and cytotoxicity. J Med Chem (2007) 1.12
Solution structural study of a DNA duplex containing the guanine-N7 adduct formed by a cytotoxic platinum-acridine hybrid agent. Biochemistry (2005) 1.10
Unprecedented monofunctional metalation of adenine nucleobase in guanine- and thymine-containing dinucleotide sequences by a cytotoxic platinum-acridine hybrid agent. J Am Chem Soc (2003) 1.09
Adenine-N3 in the DNA minor groove - an emerging target for platinum containing anticancer pharmacophores. Anticancer Agents Med Chem (2007) 1.07
Inhibition of DNA Synthesis by a Platinum-Acridine Hybrid Agent Leads to Potent Cell Kill in Non-Small Cell Lung Cancer. ACS Med Chem Lett (2011) 1.06
Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. Curr Top Med Chem (2004) 1.05
Duplex-promoted platination of adenine-N3 in the minor groove of DNA: challenging a longstanding bioinorganic paradigm. J Am Chem Soc (2005) 1.04
Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates. Biochem Pharmacol (2002) 1.03
Metal-intercalator-mediated self-association and one-dimensional aggregation in the structure of the excised major DNA adduct of a platinum-acridine agent. J Am Chem Soc (2004) 1.00
Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells. Metallomics (2012) 0.98
Unique base-step recognition by a platinum-acridinylthiourea conjugate leads to a DNA damage profile complementary to that of the anticancer drug cisplatin. Biochemistry (2004) 0.97
Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair. Mol Pharm (2011) 0.95
Characterization of the bisintercalative DNA binding mode of a bifunctional platinum-acridine agent. Nucleic Acids Res (2005) 0.94
Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin. Cancer Chemother Pharmacol (2005) 0.93
DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers. Chemistry (2012) 0.92
Unusual intercalation of acridin-9-ylthiourea into the 5'-GA/TC DNA base step from the minor groove: implications for the covalent DNA adduct profile of a novel platinum-intercalator conjugate. Nucleic Acids Res (2003) 0.92
Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents. ACS Chem Biol (2012) 0.92
Unusual Reactivity of a Potent Platinum-Acridine Hybrid Antitumor Agent. ACS Med Chem Lett (2011) 0.91
Guanine binding of a cytotoxic platinum-acridin-9-ylthiourea conjugate monitored by 1-D 1H and 2-D [1H,15N] NMR spectroscopy: hydrolysis is not the rate-determining step. J Inorg Biochem (2006) 0.90
Using a build-and-click approach for producing structural and functional diversity in DNA-targeted hybrid anticancer agents. J Med Chem (2012) 0.90
Replacement of a thiourea-S with an amidine-NH donor group in a platinum-acridine antitumor compound reduces the metal's reactivity with cysteine sulfur. J Med Chem (2009) 0.88
Biophysical characterization and molecular modeling of the coordinative-intercalative DNA monoadduct of a platinum-acridinylthiourea agent in a site-specifically modified dodecamer. J Biol Inorg Chem (2004) 0.87
The cell's nucleolus: an emerging target for chemotherapeutic intervention. ChemMedChem (2013) 0.86
Gold(I) analogues of a platinum-acridine antitumor agent are only moderately cytotoxic but show potent activity against Mycobacterium tuberculosis. J Med Chem (2009) 0.85
Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study. Chemistry (2014) 0.85
Effect of linkage geometry on biological activity in thiourea- and guanidine-substituted acridines and platinum-acridines. Bioorg Med Chem Lett (2008) 0.84
Bis(acridinylthiourea)platinum(II) complexes: synthesis, DNA affinity, and biological activity in glioblastoma cells. Bioorg Med Chem Lett (2003) 0.84
A non-crosslinking platinum-acridine hybrid agent shows enhanced cytotoxicity compared to clinical BCNU and cisplatin in glioblastoma cells. Bioorg Med Chem Lett (2005) 0.84
An improved optical tweezers assay for measuring the force generation of single kinesin molecules. Methods Mol Biol (2014) 0.83
Probing platinum-adenine-n3 adduct formation with DNA minor-groove binding agents. Chem Res Toxicol (2010) 0.82
Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents. J Med Chem (2012) 0.82
Cytotoxic acridinylthiourea and its platinum conjugate produce enzyme-mediated DNA strand breaks. Bioorg Med Chem Lett (2002) 0.81
Investigating the cellular fate of a DNA-targeted platinum-based anticancer agent by orthogonal double-click chemistry. J Biol Inorg Chem (2014) 0.81
Unexpected reactivity of the 9-aminoacridine chromophore in guanidylation reactions. J Org Chem (2007) 0.81
Interactions of a platinum-modified perylene derivative with the human telomeric G-quadruplex. J Phys Chem B (2011) 0.81
Tuning the DNA conformational perturbations induced by cytotoxic platinum-acridine bisintercalators: effect of metal cis/trans isomerism and DNA threading groups. J Med Chem (2008) 0.81
Thermally inert metal ammines as light-inducible DNA-targeted agents. Synthesis, photochemistry, and photobiology of a prototypical rhodium(III)-intercalator conjugate. Inorg Chem (2002) 0.81
Covalent immobilization of microtubules on glass surfaces for molecular motor force measurements and other single-molecule assays. Methods Mol Biol (2014) 0.81
DNA minor groove adducts formed by a platinum-acridine conjugate inhibit association of tata-binding protein with its cognate sequence. Biochemistry (2005) 0.80
Kinetically favored platination of adenine in the g-rich human telomeric repeat. J Am Chem Soc (2007) 0.80
Synthesis, structure, and reactivity of monofunctional platinum(II) and palladium(II) complexes containing the sterically hindered ligand 6-(methylpyridin-2-yl)acetate. J Inorg Biochem (2005) 0.79
Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent. Chemistry (2014) 0.79
Design of a platinum-acridine-endoxifen conjugate targeted at hormone-dependent breast cancer. Chem Commun (Camb) (2013) 0.79
PT-ACRAMTU, a platinum-acridine anticancer agent, lengthens and aggregates, but does not stiffen or soften DNA. Cell Biochem Biophys (2013) 0.77
Unexpected Assembly of a Novel Triply Bridged Diiron(II) Core by a Bidentate Schiff Base Ligand. Inorganica Chim Acta (2007) 0.77
Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups. Bioorg Med Chem Lett (2009) 0.75